Why might Caucasians require more warfarin than Asians?

The correct choice highlights a significant aspect of pharmacogenomics—the study of how genes affect a person's response to drugs. Many Asians have genetic variants that lead to slower metabolism of warfarin, primarily due to variations in genes such as CYP2C9 and VKORC1. These genetic differences can result in a lower dosage requirement for Asians compared to Caucasians, who generally metabolize warfarin at a faster rate due to different genetic backgrounds and variations.

This understanding is crucial in clinical practice, as it emphasizes the need to tailor anticoagulant therapy based on genetic makeup rather than relying solely on standardized dosing guidelines. By accounting for these pharmacogenomic factors, healthcare providers can minimize the risk of adverse effects and achieve optimal therapeutic outcomes for patients from different ethnic backgrounds.